Autobio Diagnostics Co., Ltd. (SHA:603658)

Market Cap	22.40B
Revenue (ttm)	4.32B
Net Income (ttm)	1.15B
Shares Out	571.42M
EPS (ttm)	2.00
PE Ratio	19.59
Forward PE	18.13
Dividend	1.26 (3.21%)
Ex-Dividend Date	May 26, 2025

Volume	2,119,065
Average Volume	3,102,739
Open	39.23
Previous Close	39.20
Day's Range	38.81 - 39.35
52-Week Range	36.49 - 52.98
Beta	-0.12
RSI	37.86
Earnings Date	Oct 30, 2025

About Autobio Diagnostics

Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immunoassay products consist of AutoLumo S900 and AutoLumo A1860 that provides user experience for small and medium size labs; AutoLumo A6200/A6600, an auto...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1998
• Employees: 5,773
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603658

Financial Performance

In 2024, Autobio Diagnostics's revenue was 4.47 billion, an increase of 0.62% compared to the previous year's 4.44 billion. Earnings were 1.19 billion, a decrease of -1.89%.